AC
CODX

Aristides Capital’s Co-Diagnostics CODX Stock Holding History

Aristides Capital’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-500
Closed -$15.9K – 285
2023
Q3 		$15.9K Hold
500
– – 0.01% 165
2023
Q2 		$16.6K Hold
500
– – 0.01% 167
2023
Q1 		$22.2K Hold
500
– – 0.01% 150
2022
Q4 		$37.8K Hold
500
– – 0.02% 229
2022
Q3 		$48K Sell
500
-1,500
-75% -$210K 0.04% 137
2022
Q2 		$337K Hold
2,000
– – 0.23% 101
2022
Q1 		$371K Sell
2,000
-557
-22% -$115K 0.23% 103
2021
Q4 		$685K Buy
+2,557
New +$671K 0.31% 81

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Aristides Capital's CODX Position: Q4 2023 in Review

Aristides Capital sold out of Co-Diagnostics (CODX) in Q4 2023, closing a stake of 500 shares — an estimated $15.9K sold.

Aristides Capital first reported a position in CODX in Q4 2021 and held it in 8 quarters. The position peaked at $685K in Q4 2021. 45 funds tracked by Wall St. Rank hold CODX as of Q4 2023.

  • Aristides Capital reported no remaining Co-Diagnostics position as of Q4 2023 after selling out during the quarter.
  • Aristides Capital sold 500 Co-Diagnostics shares in Q4 2023, an estimated $15.9K.
  • Aristides Capital first reported a position in Co-Diagnostics in Q4 2021 and held it in 8 quarters.
  • Aristides Capital's Co-Diagnostics position peaked at $685K in Q4 2021.
  • 45 funds tracked by Wall St. Rank held Co-Diagnostics as of Q4 2023.

Based on Aristides Capital's 13F filing for Q4 2023, filed 13 Feb 2024.